Sugi Predict

Sugi Predict / Compounds / SCHEMBL6094478

SCHEMBL6094478

SCHEMBL6094478

O=C(OC(Cc1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1)C1CCCN(C(Cc2nc3ccccc3[nH]2)c2nc3ccccc3[nH]2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ FPR1 P21462 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 3/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MAPK1 P28482 3/20 0.38
▸ ALPL P05186 1/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7238632 0.88 LMNA (0.46) LMNASMN1; SMN2KDM4EALDH1A1FPR1
SCHEMBL6095420 0.84 LMNA (0.45) LMNASMN1; SMN2KDM4EALDH1A1FPR1
SCHEMBL6092577 0.79 PDE10A (0.45) LMNASMN1; SMN2L3MBTL1HPGDTSHR
SCHEMBL6094708 0.74 HCRTR1 (0.47) LMNASMN1; SMN2KDM4EALDH1A1TSHR
SCHEMBL6094718 0.74 HCRTR1 (0.47) LMNASMN1; SMN2KDM4EALDH1A1TSHR
SCHEMBL6094061 0.73 HCRTR1 (0.44) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL6094070 0.73 HCRTR1 (0.44) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL6093822 0.71 KMT2A (0.46) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL6095523 0.71 KMT2A (0.46) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL6095618 0.70 CACNA1G (0.43) LMNASMN1; SMN2KDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030150-B2 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-04-18 — — US claimed
WO-2002092575-A1 BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 2002-11-21 — — WO claimed
US-20060142365-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-06-29 — — US disclosed
US-7030150-B2 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-04-18 — — US disclosed
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2003-06-26 — — US disclosed
WO-2002092575-A1 BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 2002-11-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142365-A1 Benzimidazole compounds and antiviral uses thereof MAVS, ZC3HAV1, TIMM13 LMNA 2346/4885SMN1; SMN2 1189/4885KDM4E 433/4885
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof MAVS, ZC3HAV1, TIMM13 LMNA 2346/4885SMN1; SMN2 1189/4885KDM4E 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.